Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).

Metenova is a leading innovator and manufacturer of magnetic mixers for pharmaceutical and biotechnology applications. The company is headquartered in Mölndal, Gothenburg.

The acquisition of Metenova strengthens Repligen's fluid management portfolio, with a product line that expands on the success of Repligen's systems and fluid management assemblies.

Vinge's team mainly consisted of Jonas Bergström, Johanna Wiberg, Viktor Lennartsson, Robin Sultani (M&A), Sam Seddigh, Hanna Marberg (employment), David Olander (competition), Mathilda Persson, Mika Jordan, Arthur Kinski, Mario Saad (commercial agreements), Christoffer Nordin (Life Science/Regulatory), Lisa Hörnqvist (IT and GDPR), Stojan Arnerstål, Axel Lennartsson, Johan Gavelin (IP), Kristoffer Larson (real property), Mia Falk (compliance), Anders Leissner (sanctions/export control) and Cecilia Loctander (project assistant).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025